- Home
- EXAS
as 11-15-2024 4:00pm EST
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 12.3B | IPO Year: | N/A |
| Target Price: | $73.07 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $40.62 - $79.62 | Next Earning Date: | 11-05-2024 |
| Revenue: | $2,692,328,000 | Revenue Growth: | 11.91% |
| Revenue Growth (this year): | 12.41% | Revenue Growth (next year): | 11.64% |
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baranick Brian | EXAS | EVP, GM, Precision Oncology | Oct 8 '24 | Sell | $70.00 | 929 | $65,030.00 | 12,758 | |
| Baranick Brian | EXAS | EVP, GM, Precision Oncology | Sep 18 '24 | Sell | $70.00 | 929 | $65,030.00 | 12,758 |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock
Clinical Trials Arena
2 days ago
Exact Sciences showcases early cancer detection test data at AACR meeting
Argus Research
3 days ago
Daily – Vickers Top Buyers & Sellers for 11/14/2024
MT Newswires
4 days ago
Exact Sciences Insider Bought Shares Worth $1,001,325, According to a Recent SEC Filing
Business Wire
4 days ago
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Insider Monkey
6 days ago
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
MedTech Dive
9 days ago
Exact Sciences’ forecast cut shocks analysts
Investor's Business Daily
10 days ago
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.